- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Impact of apitherapy on canine, equine, and chicken lymphocytes, in vitro. (Pubmed Central) - Jan 14, 2024
Concanavalin A (Con A) and dexamethasone were used as stimulatory and suppressive controls, respectively...Honeybee venom was the strongest PBL stimulant for all three species and in the equine, surpassed the stimulant response of Con A and yet, enhanced PBL cell viability post culture. In summary, the results of this preliminary in vitro study show that these three honeybee products do impact lymphocyte proliferation and viability in dogs, horses, and chickens, and that more research both in vitro and in vivo will be necessary to draw conclusions regarding their future use as immune stimulants or inhibitors.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma
Retrospective data, Journal: Clinical features of pneumothorax associated with COVID-19: A retrospective analysis of two centres. (Pubmed Central) - Jan 12, 2024
Pneumothorax associated with COVID-19 was more common in patients with moderate or severe disease requiring oxygenation, and occurred within 1 month of COVID-19 diagnosis. Pneumothorax associated with COVID-19 is a serious complication with a high mortality rate and clinicians should pay attention to it.
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Trial primary completion date, Surgery: Opioid-Free Pain Protocol After Shoulder Arthroplasty (clinicaltrials.gov) - Jan 11, 2024
P4, N=80, Recruiting,
Trial primary completion date: Mar 2024 --> Nov 2024 Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| dexamethasone / Generic mfg.
Journal: Dexamethasone release from hyaluronic acid microparticle and proanthocyanidin-gelatin hydrogel in sciatic tissue regeneration. (Pubmed Central) - Jan 11, 2024
Interestingly, histological analysis revealed a significant increase in the number of axons in the injured sciatic nerve following treatment with Dex-HA-Tyr Mp and injectable Gela-PA hydrogel compared to other control groups. In conclusion, the results demonstrated that fabricated Dex-loaded MPs and injectable hydrogel from biomimetic components are suitable systems for sustained delivery of Dex with adequate biocompatibility and the approach may have potential therapeutic applications in peripheral nerve regeneration.
- |||||||||| sirolimus / Generic mfg.
Review, Journal: Sirolimus potentiated angioedema: A case report and review of the literature. (Pubmed Central) - Jan 11, 2024
Transplant physicians should be aware of the life-threatening interaction between ACE inhibitors and mTOR-Is like sirolimus. Consideration should be given to switching from an ACE inhibitor to an angiotensin-receptor blocker when initiating patients on mTOR-Is.
- |||||||||| dexamethasone cyclodextrin nanoparticle ophthalmic suspension (OCS-01) / Oculis
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Surgery: OPTIMIZE-2: Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery (clinicaltrials.gov) - Jan 11, 2024
P3, N=160, Recruiting,
Our study suggested that concurrent intravitreal TA injection following ERM removal did not provide additional benefits regarding anatomical and visual improvement in iERM cases classified as Stages 2 and 3. Not yet recruiting --> Recruiting
- |||||||||| Darzalex (daratumumab) / J&J
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma (clinicaltrials.gov) - Jan 11, 2024
P2, N=1, Terminated,
Not yet recruiting --> Recruiting N=43 --> 1 | Trial completion date: May 2026 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Nov 2023; Low Accrual
- |||||||||| Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: MiSTIC: Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA (clinicaltrials.gov) - Jan 11, 2024
P4, N=320, Active, not recruiting,
N=43 --> 1 | Trial completion date: May 2026 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Nov 2023; Low Accrual Recruiting --> Active, not recruiting | N=1400 --> 320 | Trial completion date: Jul 2024 --> Apr 2024 | Trial primary completion date: Jul 2024 --> Apr 2024
- |||||||||| triamcinolone acetonide / Generic mfg.
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Head-to-Head: The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Jan 11, 2024
P4, N=327, Recruiting,
Recruiting --> Active, not recruiting | N=1400 --> 320 | Trial completion date: Jul 2024 --> Apr 2024 | Trial primary completion date: Jul 2024 --> Apr 2024 Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Feb 2025 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Apr 2024 --> Dec 2024
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Trial completion date, Trial primary completion date: Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma (clinicaltrials.gov) - Jan 11, 2024
P2, N=40, Recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Feb 2025 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Apr 2024 --> Dec 2024 Trial completion date: Jan 2024 --> Jan 2034 | Trial primary completion date: Jan 2024 --> Jan 2034
- |||||||||| Empliciti (elotuzumab) / AbbVie, BMS
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) (clinicaltrials.gov) - Jan 11, 2024
P2, N=8, Terminated,
Phase classification: P1b/2 --> P2 | Trial completion date: Sep 2027 --> Jun 2027 | Trial primary completion date: Mar 2025 --> Jul 2025 N=75 --> 8 | Trial completion date: Nov 2026 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Jan 2024; The study was terminated early based on disease flare/lack of efficacy in the early phase of the trial.
- |||||||||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment open: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Jan 11, 2024
P3, N=105, Recruiting,
N=75 --> 8 | Trial completion date: Nov 2026 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Jan 2024; The study was terminated early based on disease flare/lack of efficacy in the early phase of the trial. Active, not recruiting --> Recruiting
- |||||||||| hydrocortisone / Generic mfg.
Association Between Weiss-Kruszka Syndrome (WSKA) and Obesity (MTCC - Exhibit Halls DE) - Jan 10, 2024 - Abstract #ACMG2024ACMG_753;
To delve deeper into this association and elucidate the relationship between WSKA and failure to thrive, larger case series are warranted. Previous data suggests that failure to thrive in WSKA is primarily secondary to feeding difficulties rather than an intrinsic concern.
- |||||||||| hydrocortisone / Generic mfg.
Expansion of TAOK1 Related Developmental Delay Phenotype (MTCC - Exhibit Halls DE) - Jan 10, 2024 - Abstract #ACMG2024ACMG_526;
P
To our knowledge, heart defects, endocrinopathies and/or mitochondrial dysfunction have not been previously reported and may represent an expansion of the phenotype. Mitochondrial and neuronal abnormalities have been reported in the axons of knockdown flies, including disturbed mitochondrial distribution and significantly decreased mitochondrial size.
- |||||||||| dexamethasone / Generic mfg.
Journal: Photodegradation kinetics and halogens release of the emerging concern pollutants dexamethasone and S-metolachlor on TiO/rGO composites. (Pubmed Central) - Jan 10, 2024
In the experiments with DEX solutions a different behaviour was observed; the released F in the photocatalytic degradation was partially adsorbed on the catalyst surface, but the adsorption capacity decreased with the use of the photocatalyst in consecutive cycles until the solubilised F matched the degraded concentration of DEX. Furthermore, the mass balance between the degraded contaminant and the solubilised halogen anion, for both contaminants, allowed to conclude the absence of halogenated intermediates under the final operating conditions, that is a remarkable outcome in water remediation processes.
- |||||||||| arsenic trioxide / Generic mfg., budesonide / Generic mfg.
Journal: A case report of acute promyelocytic leukemia with mycosis fungoides. (Pubmed Central) - Jan 9, 2024
All-trans-retinoicacid in the treatment of APL must be given attention mycosis fungoides. Early diagnosis can guide accurate treatment, which is of great help in alleviating the pain of patients and improving the cure rate.
- |||||||||| remdesivir / Generic mfg., dexamethasone / Generic mfg.
Journal: Pediatric COVID-19 Hospitalizations During the Omicron Surge. (Pubmed Central) - Jan 9, 2024
Return to the emergency department for ongoing COVID-19 symptoms was uncommon (4%). Patients with croup, a presentation seen more commonly with the omicron variant than previously, appeared to do well without remdesivir.
- |||||||||| Simulect (basiliximab) / Novartis, Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Heart and Lung Transplant in a Patient with Relapsed AL Amyloidosis (Board #133; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1659;
Standard of care previously included cyclophosphamide, bortezomib, and dexamethasone (CyBorD)...She was given induction therapy with basiliximab and maintenance triple drug immunosuppression consisting of tacrolimus, mycophenolate mofetil, and prednisone. Over the first 6-month period, she has been stable without any allograft rejection or transplant-related complications.Summary This case highlights the short-term successful outcome of a heart-lung transplant recipient for AL amyloidosis as a result of contemporary plasma cell-directed therapies availability.
- |||||||||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Thinking Outside the Box: dd-cfDNA and Gene-Expression Profiling in Combined Heart-Liver Transplantation (CHLT) (Board #100; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1654;
Following Valcyte, AS fell...AS levels (0.12-1.4%) fell with 8 weeks of Mavyret...Treated with solumedrol, ATG & pheresis...In this series, viral infection (HCV, CMV, COVID) was the likely cause or contributor to dd-cfDNA elevation. Further study is warranted to understand these markers in CHLT.
- |||||||||| Simulect (basiliximab) / Novartis
Hemophagocytic Lymphohistiocytosis: A Rare Diagnosis in the Immediate Aftermath of Lung Transplantation (Board #243; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1544;
Induction regimen included basiliximab, mycophenolate and methylprednisolone...High dose dexamethasone was started & patient was deemed clinically unstable for etoposide...It is underrecognized due to non-specific presenting symptoms and lack of association with lung transplantation. It is critical to have a high index of suspicion in patients who develop manifestations of HLH to facilitate timely treatment of this often-fatal disease.
- |||||||||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
Road to PML is Paved with Immunosuppression: Rare Case of PML After Lung Transplantation (Board #254; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1538;
His post-tx course was complicated by concern for acute cellular rejection in setting of decline in pulmonary function tests, treated with IV methylprednisolone 1g for 3 days with 10-day steroid taper back to baseline and valganciclovir treated CMV in BAL, both 1 month prior...This was treated with IVIG, decreased IS regimen, and mirtazapine to target the same receptor mediating JCV entry into CNS...His mental status worsened and with evidence of disease progression, his family transitioned to hospice.Summary PML is a rare but detrimental complication of lung transplant with incidence of 1.24 per 1000 SOT years for heart and lung. While uncommon, PML should be considered in lung transplant patients presenting with neurologic symptoms and further investigation is needed to identify whether screening patients pre-transplant for JCV exposure has benefit.
- |||||||||| Simulect (basiliximab) / Novartis, Mycobutin (rifabutin) / Pfizer, Lupin, bocidelpar (MA-0211) / Astellas
Disseminated Mycobacterium Tuberculosis Post Lung Transplantation (Board #245; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1536;
Induction immunosuppression (ISN) included basiliximab, mycophenolate (MMF) & solumedrol followed by maintenance ISN of tacrolimus (FK,10-12 ng/ml), MMF, & prednisone...Prednisone dose was 20 mg a day while on rifabutin...Rapid onset & dissemination of MTB 1 month after the transplant makes our case unique.Donor was a young female, who moved from Mexico...This brings up the inquiry of whether & how to screen the donors for LTBI. The limitation would be both TST & IGRA might not be feasible due to time constraints and AFB cultures on BAL if sent, will be finalized after organ is transplanted.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Lung Transplant Recipients: A Multicenter French Study (Board #219; Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1514;
Regarding immunosuppressive maintenance treatment, 20 patients were treated with tacrolimus, 22 with mycophenolate mofetil and 25 with steroids...21 patients received dexamethasone, 7 had Tocilizumab and 1 had Remdesivir...No patient was treated with Nirmatrelvir/Ritonavir...The average FEV1 loss was 0.138ml (-4.81%).Conclusion This study showed that CP use was limited and heterogenous between the French LT centers, including an important variability in the time from disease onset to CP administration. This is the first and largest multicenter study assessing the use of CP in LT patients, further studies will be required to drive future guidelines.
|
